Ranibizumab: The clinician's guide to commencing, continuing, and discontinuing treatment.
Amoaku
W
W
Scientific Department, The Royal College of Ophthalmologists, Regent's Park, UK. Wma@nottingham.ac.uk
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D020256:Choroidal Neovascularization / Q000188:drug therapy*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D008268:Macular Degeneration / Q000188:drug therapy*; D000069579:Ranibizumab; D006113:United Kingdom
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors; D000069579:Ranibizumab